The recent introduction of immune checkpoint inhibitors has revolutionized the therapeutic landscape of ESCC patients with advanced/metastatic disease, and the combination of an agent targeting PD1 or PD-L1 with chemotherapy is now the standard of care for these patients. Here, CD274 is linked to metastatic neoplasm.